NEONC Acquires AI & Bioprinting IP for Brain Cancer Drug Discovery – $3.5M Deal
Investors and biotech innovators: NEONC Technologies Holdings has announced a $3.5 million acquisition deal targeting breakthrough drug discovery tools for brain cancer. The acquired Delaware entity, co-owned by Dr. Ishmar K. Puri and Beth R. Levinson, brings a cutting-edge IP portfolio spanning 3D bioprinting, AI, and quantum modeling.
📌 Highlights:
Focused on brain cancer drug discovery
Deal includes both cash and stock
Dr. Ishmar K. Puri to join NEONC’s board
Strategic expansion into advanced biotech and computational modeling
This move signals NEONC’s commitment to next-gen therapies through technological innovation.
🔖 YouTube Tags:
#NEONC #BiotechNews #BrainCancerResearch #3DBioprinting #ArtificialIntelligence #QuantumModeling #DrugDiscovery #HealthTech #MedTechInnovation #BiotechInvesting #NeoncTechnologies #NewsOut #JaneKing #NYSE #Biopharma
